These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy. Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217 [TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535 [TBL] [Abstract][Full Text] [Related]
14. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case. Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788 [TBL] [Abstract][Full Text] [Related]
15. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Lebas E; Marchal N; Rorive A; Nikkels AF Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680 [TBL] [Abstract][Full Text] [Related]
16. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy. Lu D; Xu Z; Zhang D; Jiang M; Liu K; He J; Ma D; Ma X; Tan S; Gao GF; Chai Y Front Immunol; 2022; 13():826045. PubMed ID: 35309324 [TBL] [Abstract][Full Text] [Related]
17. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Hernández-Guerrero T; Doger B; Moreno V Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085 [TBL] [Abstract][Full Text] [Related]
18. Cemiplimab: First Global Approval. Markham A; Duggan S Drugs; 2018 Nov; 78(17):1841-1846. PubMed ID: 30456447 [TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockades in gynecological cancers: A review of clinical trials. Peng H; He X; Wang Q Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489 [TBL] [Abstract][Full Text] [Related]
20. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]